|
1
|
Cancer Institute NSW. Cancer in New South
Wales: Incidence, Mortality and Prevalence 2005. Cancer Institute
NSW; Sydney: 2007
|
|
2
|
National Cancer Institute: Cancer Trends
Progress Report - 2007 Update. National Cancer Institute; Bethesda,
MD: 2007
|
|
3
|
National Cancer Institute. A Snapshot of
Pancreatic Cancer. National Cancer Institute; Bethesda, MD:
2007
|
|
4
|
Australian Institute of Health and Welfare
(AIHW) and Australasian Association of Cancer Registries (AACR).
Cancer in Australia: an overview, 2008. AIHW and AACR; Canberra:
2008
|
|
5
|
American Cancer Society. Cancer Facts and
Figures 2008. American Cancer Society; Atlanta, GA: 2008
|
|
6
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
American Cancer Society. Cancer Facts and
Figures 2007. American Cancer Society; Atlanta, GA: 2007
|
|
8
|
Von Hoff DD, Evans DB and Hruban RH:
Pancreatic Cancer. 1st edition. Jones and Bartlett Publishers;
Sudbury, MA: 2005
|
|
9
|
Chang DK, Merrett ND and Biankin AV: NSW
Pancreatic Cancer Network: Improving outcomes for operable
pancreatic cancer: is access to safer surgery the problem? J
Gastroenterol Hepatol. 23:1036–1045. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Glaser KB: HDAC inhibitors: clinical
update and mechanism-based potential. Biochem Pharmacol.
74:659–671. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duvic M, Talpur R, Ni X, et al: Phase 2
trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA)
for refractory cutaneous T-cell lymphoma (CTCL). Blood. 109:31–39.
2007. View Article : Google Scholar
|
|
12
|
Zhang C, Richon V, Ni X, Talpur R and
Duvic M: Selective induction of apoptosis by histone deacetylase
inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to
mechanism of therapeutic action. J Invest Dermatol. 125:1045–1052.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gore SD: Combination therapy with DNA
methyltransferase inhibitors in hematologic malignancies. Nat Clin
Pract Oncol. 2(Suppl 1): S30–S35. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Issa JP and Byrd JC: Decitabine in chronic
leukemias. Semin Hematol. 42(Suppl 2): S43–S49. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Batty N, Malouf GG and Issa JP: Histone
deacetylase inhibitors as anti-neoplastic agents. Cancer Lett.
280:192–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Flotho C, Claus R, Batz C, et al: The DNA
methyltransferase inhibitors azacitidine, decitabine and zebularine
exert differential effects on cancer gene expression in acute
myeloid leukemia cells. Leukemia. 23:1019–1028. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Laurenzana A, Petruccelli LA, Pettersson
F, et al: Inhibition of DNA methyltransferase activates tumor
necrosis factor alpha-induced monocytic differentiation in acute
myeloid leukemia cells. Cancer Res. 69:55–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Munster PN, Troso-Sandoval T, Rosen N,
Rifkind R, Marks PA and Richon VM: The histone deacetylase
inhibitor suberoylanilide hydroxamic acid induces differentiation
of human breast cancer cells. Cancer Res. 61:8492–8497.
2001.PubMed/NCBI
|
|
19
|
Shiozawa K, Nakanishi T, Tan M, et al:
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid)
combined with cytosine arabinoside and etoposide for treatment of
acute leukemias. Clin Cancer Res. 15:1698–1707. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu WS, Parmigiani RB and Marks PA: Histone
deacetylase inhibitors: molecular mechanisms of action. Oncogene.
26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Buchwald M, Krämer OH and Heinzel T: HDACi
- targets beyond chromatin. Cancer Lett. 280:160–167. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nolan L, Johnson PW, Ganesan A, Packham G
and Crabb SJ: Will histone deacetylase inhibitors require
combination with other agents to fulfil their therapeutic
potential? Br J Cancer. 99:689–694. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gui CY, Ngo L, Xu WS, Richon VM and Marks
PA: Histone deacetylase (HDAC) inhibitor activation of
p21WAF1 involves changes in promoter-associated
proteins, including HDAC1. Proc Natl Acad Sci USA. 101:1241–1246.
2004. View Article : Google Scholar
|
|
24
|
Arnold NB, Arkus N, Gunn J and Korc M: The
histone deacetylase inhibitor suberoylanilide hydroxamic acid
induces growth inhibition and enhances gemcitabine-induced cell
death in pancreatic cancer. Clin Cancer Res. 13:18–26. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eyüpoglu IY, Hahnen E, Buslei R, et al:
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma
properties in vitro, ex vivo and in vivo. J Neurochem. 93:992–999.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kumagai T, Wakimoto N, Yin D, et al:
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid
(Vorinostat, SAHA) profoundly inhibits the growth of human
pancreatic cancer cells. Int J Cancer. 121:656–665. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hurd PJ, Whitmarsh AJ, Baldwin GS, et al:
Mechanism-based inhibition of C5-cytosine DNA methyltransferases by
2-H pyrimidinone. J Mol Biol. 286:389–401. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
29
|
Jackson-Grusby L, Beard C, Possemato R, et
al: Loss of genomic methylation causes p53-dependent apoptosis and
epigenetic deregulation. Nat Genet. 27:31–39. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Scott SA, Lakshimikuttysamma A, Sheridan
DP, Sanche SE, Geyer CR and DeCoteau JF: Zebularine inhibits human
acute myeloid leukemia cell growth in vitro in association with
p15INK4B demethylation and reexpression. Exp Hematol. 35:263–273.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gilbert J, Gore SD, Herman JG and Carducci
MA: The clinical application of targeting cancer through histone
acetylation and hypomethylation. Clin Cancer Res. 10:4589–4596.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sato N, Fukushima N, Maehara N, et al:
SPARC/osteonectin is a frequent target for aberrant methylation in
pancreatic adenocarcinoma and a mediator of tumor-stromal
interactions. Oncogene. 22:5021–5030. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sato N, Parker AR, Fukushima N, et al:
Epigenetic inactivation of TFPI-2 as a common mechanism associated
with growth and invasion of pancreatic ductal adenocarcinoma.
Oncogene. 24:850–858. 2005. View Article : Google Scholar
|
|
34
|
Fu B, Guo M, Wang S, et al: Evaluation of
GATA-4 and GATA-5 methylation profiles in human pancreatic cancers
indicate promoter methylation patterns distinct from other human
tumor types. Cancer Biol Ther. 6:1546–1552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Abe T, Toyota M, Suzuki H, et al:
Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes
pancreatic cancer cells to hypoxia-mediated cell death. J
Gastroenterol. 40:504–510. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamada N, Nishida Y, Tsutsumida H, et al:
MUC1 expression is regulated by DNA methylation and histone H3
lysine 9 modification in cancer cells. Cancer Res. 68:2708–2716.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yamada N, Hamada T, Goto M, et al: MUC2
expression is regulated by histone H3 modification and DNA
methylation in pancreatic cancer. Int J Cancer. 119:1850–1857.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vincent A, Ducourouble MP and Van
Seuningen I: Epigenetic regulation of the human mucin gene MUC4 in
epithelial cancer cell lines involves both DNA methylation and
histone modifications mediated by DNA methyltransferases and
histone deacetylases. FASEB J. 22:3035–3045. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yonezawa S, Goto M, Yamada N, Higashi M
and Nomoto M: Expression profiles of MUC1, MUC2, and MUC4 mucins in
human neoplasms and their relationship with biological behavior.
Proteomics. 8:3329–3341. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Omura N and Goggins M: Epigenetics and
epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol.
2:310–326. 2009.PubMed/NCBI
|
|
41
|
Furukawa T, Duguid WP, Rosenberg L,
Viallet J, Galloway DA and Tsao MS: Long-term culture and
immortalization of epithelial cells from normal adult human
pancreatic ducts transfected by the E6E7 gene of human papilloma
virus 16. Am J Pathol. 148:1763–1770. 1996.PubMed/NCBI
|
|
42
|
Vonlaufen A, Joshi S, Qu C, et al:
Pancreatic stellate cells: partners in crime with pancreatic cancer
cells. Cancer Res. 68:2085–2093. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Probst AV, Dunleavy E and Almouzni G:
Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell
Biol. 10:192–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Missiaglia E, Donadelli M, Palmieri M,
Crnogorac-Jurcevic T, Scarpa A and Lemoine NR: Growth delay of
human pancreatic cancer cells by methylase inhibitor
5-aza-2′-deoxycytidine treatment is associated with activation of
the interferon signalling pathway. Oncogene. 24:199–211. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Butler LM, Agus DB, Scher HI, et al:
Suberoylanilide hydroxamic acid, an inhibitor of histone
deacetylase, suppresses the growth of prostate cancer cells in
vitro and in vivo. Cancer Res. 60:5165–5170. 2000.PubMed/NCBI
|
|
47
|
Butler LM, Zhou X, Xu WS, et al: The
histone deacetylase inhibitor SAHA arrests cancer cell growth,
up-regulates thioredoxin-binding protein-2, and down-regulates
thioredoxin. Proc Natl Acad Sci USA. 99:11700–11705. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Marks PA and Breslow R: Dimethyl sulfoxide
to vorinostat: development of this histone deacetylase inhibitor as
an anticancer drug. Nat Biotechnol. 25:84–90. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Henderson C, Mizzau M, Paroni G, Maestro
R, Schneider C and Brancolini C: Role of caspases, Bid, and p53 in
the apoptotic response triggered by histone deacetylase inhibitors
trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J
Biol Chem. 278:12579–12589. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Polo SE and Almouzni G: Histone metabolic
pathways and chromatin assembly factors as proliferation markers.
Cancer Lett. 220:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Koundrioukoff S, Polo S and Almouzni G:
Interplay between chromatin and cell cycle checkpoints in the
context of ATR/ATM-dependent checkpoints. DNA Repair (Amst).
3:969–978. 2004. View Article : Google Scholar
|
|
53
|
Graham JS, Kaye SB and Brown R: The
promises and pitfalls of epigenetic therapies in solid tumours. Eur
J Cancer. 45:1129–1136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Polo SE and Almouzni G: DNA damage leaves
its mark on chromatin. Cell Cycle. 6:2355–2359. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Vrana JA, Decker RH, Johnson CR, et al:
Induction of apoptosis in U937 human leukemia cells by
suberoylanilide hydroxamic acid (SAHA) proceeds through pathways
that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but
independent of p53. Oncogene. 18:7016–7025. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Abbas T and Dutta A: p21 in cancer:
intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mills J, Hricik T, Siddiqi S and
Matushansky I: Chromatin structure predicts epigenetic therapy
responsiveness in sarcoma. Mol Cancer Ther. 10:313–324. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yin D, Ong JM, Hu J, et al:
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor:
effects on gene expression and growth of glioma cells in vitro and
in vivo. Clin Cancer Res. 13:1045–1052. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Vijayaraghavalu S, Dermawan JK, Cheriyath
V and Labhasetwar V: Highly synergistic effect of sequential
treatment with epigenetic and anticancer drugs to overcome drug
resistance in breast cancer cells is mediated via activation of p21
gene expression leading to G2/M cycle arrest. Mol Pharm.
10:337–352. 2013. View Article : Google Scholar :
|
|
60
|
Carew JS, Nawrocki ST and Cleveland JL:
Modulating autophagy for therapeutic benefit. Autophagy. 3:464–467.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Robert T, Vanoli F, Chiolo I, et al: HDACs
link the DNA damage response, processing of double-strand breaks
and autophagy. Nature. 471:74–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Dokmanovic M, Perez G, Xu W, et al:
Histone deacetylase inhibitors selectively suppress expression of
HDAC7. Mol Cancer Ther. 6:2525–2534. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Mitsiades CS, Mitsiades NS, McMullan CJ,
et al: Transcriptional signature of histone deacetylase inhibition
in multiple myeloma: biological and clinical implications. Proc
Natl Acad Sci USA. 101:540–545. 2004. View Article : Google Scholar :
|
|
64
|
Cooper AL, Greenberg VL, Lancaster PS, van
Nagell JR Jr, Zimmer SG and Modesitt SC: In vitro and in vivo
histone deacetylase inhibitor therapy with suberoylanilide
hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol
Oncol. 104:596–601. 2007. View Article : Google Scholar
|
|
65
|
Nimmanapalli R, Fuino L, Stobaugh C,
Richon V and Bhalla K: Cotreatment with the histone deacetylase
inhibitor suberoylanilide hydroxamic acid (SAHA) enhances
imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia
cells. Blood. 101:3236–3239. 2003. View Article : Google Scholar
|
|
66
|
Holzman DC: Pancreatic cancer: will
incremental advances begin to make a difference? J Natl Cancer
Inst. 102:1821–1823. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Neoptolemos JP, Dunn JA, Stocken DD, et
al: Adjuvant chemoradiotherapy and chemotherapy in resectable
pancreatic cancer: a randomised controlled trial. Lancet.
358:1576–1585. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Neoptolemos JP, Stocken DD, Bassi C, et
al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs
gemcitabine following pancreatic cancer resection: a randomized
controlled trial. JAMA. 304:1073–1081. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
O’Reilly EM: Refinement of adjuvant
therapy for pancreatic cancer. JAMA. 304:1124–1125. 2010.
View Article : Google Scholar
|
|
70
|
Mohammed A, Janakiram NB, Li Q, et al: The
epidermal growth factor receptor inhibitor gefitinib prevents the
progression of pancreatic lesions to carcinoma in a conditional
LSL-KrasG12D/+ transgenic mouse model. Cancer Prev Res (Phila).
3:1417–1426. 2010. View Article : Google Scholar
|
|
71
|
Appleton K, Mackay HJ, Judson I, et al:
Phase I and pharmacodynamic trial of the DNA methyltransferase
inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol.
25:4603–4609. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Venturelli S, Berger A, Weiland T, et al:
Dual antitumour effect of 5-azacytidine by inducing a breakdown of
resistance-mediating factors and epigenetic modulation. Gut.
60:156–165. 2011. View Article : Google Scholar
|
|
73
|
Shakya R, Gonda T, Quante M, et al:
Hypomethylating therapy in an aggressive stroma-rich model of
pancreatic carcinoma. Cancer Res. 73:885–896. 2013. View Article : Google Scholar :
|
